Edvan Q. Crusoe
Salvador, BA, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Real-world outcomes of daratumumab, bortezomib, thalidomide and dexamethasone (Dara-VTd) induction and lenalidomide maintenance in transplant-eligible multiple myeloma.
Journal: British journal of haematology
Published: May 19, 2026
Brazilian consensus recommendations on the diagnosis and treatment of light chain amyloidosis.
Journal: Hematology, transfusion and cell therapy
Published: April 30, 2026
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.
Journal: Leukemia & lymphoma
Published: October 03, 2025
Practical Guidance on the Clinical Management of Ocular Adverse Events Associated with Belantamab Mafodotin for Patients with Relapsed/Refractory Multiple Myeloma: Latin American Expert Panel Recommendations.
Journal: Oncology and therapy
Published: April 24, 2025
Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.
Journal: Cancers
Published: June 11, 2023
CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil.
Journal: Hematology, transfusion and cell therapy
Published: August 30, 2022
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors.
Journal: American journal of hematology
Published: January 19, 2022
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Journal: The New England journal of medicine
Published: June 30, 2021
Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases.
Journal: Leukemia & lymphoma
Published: July 24, 2018
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.
Journal: Leukemia & lymphoma
Published: July 03, 2018
Last Updated: 09/26/2026